Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007155
Abstract: Key Points • HDAC1 inhibition dampens IRF4 transcription through histone hyperacetylation, thereby reducing the expression of the survival mediator PIM2.• Simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 represents an efficient therapeutic… read more here.
Keywords: irf4 axis; therapeutic option; inhibition; hdac1 irf4 ... See more keywords